VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs VNRX 5133 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; First in man
- Sponsors VenatoRx Pharmaceuticals
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 11 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.